Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats

References

• Abelmann WH. (1984). Classification and natural history of primary myocardial disease. Prog Cardiovasc Dis 27:73–94
   PubMed Web of Science ®Google Scholar
• Al-Harbi NO, Imam F, Nadeem A, et al (2014a). Carbon tetrachloride-induced hepatotoxicity in rat is reversed by treatment with riboflavin. Int Immunopharmacol 21:383–8
   PubMed Web of Science ®Google Scholar
• Al-Harbi NO, Imam F, Nadeem A. (2014b). Protection against tacrolimus-induced cardiotoxicity in rats by olmesartan and aliskiren. Toxicol Mech Methods Mech 24:697–702
   PubMed Web of Science ®Google Scholar
• Al-Harbi NO, Imam F, Nadeem A, et al (2015). Riboflavin attenuates lipopolysaccharide-induced lung injury in rats. Toxicol Mech Methods Mech 25:417–23
   PubMed Web of Science ®Google Scholar
• Al-Shabanah O, Aleisa AM, Hafez MM, et al (2012). Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-β/Smad p53 pathway in rat model. Oxid Med Cell Longev 2012:1–7
   Web of Science ®Google Scholar
• Barry SP, Davidson SM, Townsend PA. (2008). Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40:2023–39
   PubMed Web of Science ®Google Scholar
• Brandes RP, Kreuzer J. (2005). Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 65:16–27
   PubMed Web of Science ®Google Scholar
• Chari A, Hajje D. (2014). Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer 14:1–9
   PubMed Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, et al (2007). Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67:6383–91
   PubMed Web of Science ®Google Scholar
• Hajek R, Bryce R, Ro S, et al (2012). Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer 12:1–7
   PubMed Web of Science ®Google Scholar
• Inoue M. (2011). Protective mechanisms against reactive oxygen species. In Arias IM, Boyer JL, Fausto N, et al, eds. The liver: biology and pathobiology. 5th ed. New York: Raven Press, 443–59
   Google Scholar
• Jakubowiak AJ. (2014). Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview. Cancer Treat Rev 40:781–90
   PubMed Web of Science ®Google Scholar
• Konukoglu D, Serin O, Kemerli DG, et al (1998). A study on the carotid artery intima-media thickness and its association with lipid peroxidation. Clin Chim Acta 277:91–8
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosenburg NJ, Farr AL, et al (1951). Protein measurement with the Folin phenol reagent. . J Biol Chem 193:265–75
   PubMed Web of Science ®Google Scholar
• Mansour MA, Aljoufi MA, Al-Hosaini K, et al (2014). Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma. Chem Biol Interact 215:17–24
   PubMed Web of Science ®Google Scholar
• McBride L, Samuel CO. (2013). The side effect profile of carfilzomib: from clinical trials to clinical practice. J Adv Pract Oncol 4:22–30
   Google Scholar
• Miyata S, Minobe W, Bristow MR, et al (2000). Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 86:386–90
   PubMed Web of Science ®Google Scholar
• Neckar J, Boudikova A, Mandikova P, et al (2012). Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts. Can J Physiol Pharmacol 90:1303–10
   PubMed Web of Science ®Google Scholar
• Nooka AK. (2013). Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology (Williston Park) 27:11–18
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Oshishi N, Yagi K. (1979). Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction. Anal Biochem 95:351–8
   PubMed Web of Science ®Google Scholar
• Panda VS, Naik SR. (2009). Evaluation of cardioprotective activity of Ginkgo biloba and Ocimum sanctum in rodents. Altern Med Rev 14:161--71
   PubMed Web of Science ®Google Scholar
• Piura B, Rabinovich A. (2005). Doxorubicin and ifosfamidemesna in advanced and recurrent uterine sarcomas. Eur J Gynaecol Oncol 26:275–8
   PubMed Web of Science ®Google Scholar
• Popelova O, Sterba M, Haskova P, et al (2009). Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer 101:792–802
   PubMed Web of Science ®Google Scholar
• Redic K. (2013). Carfilzomib: a novel agent for multiple myeloma. J Pharm Pharmacol 65:1095–106
   PubMed Web of Science ®Google Scholar
• Reiser PJ, Portman MA, Ning XH, et al (2001). Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles. Am J Physiol Heart Circ Physiol J Physiol Heart Circ 280:H1814–20
   PubMed Web of Science ®Google Scholar
• Repetto A, Dal Bello B, Pasotti M, et al (2005). Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur Heart J 26:1519–27
   PubMed Web of Science ®Google Scholar
• Richardson P, McKenna W, Bristow M, et al (1996). Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93:841–2
   PubMed Web of Science ®Google Scholar
• Sedlak J, Lindsay RH. (1968). Estimation of total, protein bound and non-protein bound sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205
   PubMed Web of Science ®Google Scholar
• Seifert CF, Nesser ME, Thompson DF. (1994). Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28:1063–72
   PubMed Web of Science ®Google Scholar
• Shanmugarajan TS, Arunsunder M, Somasundaram I, et al (2008). Protective effect of Ficus hispida Linn. on cyclophosphamide provoked oxidative myocardial injury in rat model. Int J Pharmacol 1:1–10
   Google Scholar
• Siegel D, Martin T, Nooka A, et al (2013). Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase ii clinical studies. Haematologica 98:1753–61
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M, et al (2012). A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120:2817–25
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N. (1998). Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900–5
   PubMed Web of Science ®Google Scholar
• Tipnis UR, He GY, Li S, et al (2000). Attenuation of isoproterenol-mediated myocardial injury in rat by an inhibitor of polyamine synthesis. Cardiovasc Pathol 9:273–80
   PubMed Web of Science ®Google Scholar
• Vij R, Siegel DS, Jagannath S, et al (2012). An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 158:739–48
   PubMed Web of Science ®Google Scholar
• WHO Report (1980). Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 44:672–3
   PubMedGoogle Scholar
• Wu G, Fang YZ, Yang S, et al (2004). Glutathione metabolism and its implications for health. J Nutr 134:489–92
   PubMed Web of Science ®Google Scholar
• Yeh ETH, Tong AT, Lenihan DJ, et al (2004). Review: current perspective: cardiovascular complications of cancer therapy diagnosis, pathogenesis, and management. Circulation 109:3122–31
   PubMed Web of Science ®Google Scholar
• Zhang S, Meng T, Liu J, et al (2015). Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2. Medicine 94:1–8
   Web of Science ®Google Scholar